End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,850 KRW | +0.71% | -4.04% | -33.18% |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
69.5
%
| 3,437 | 64.9 % | 2,172 | 69.5 % | -36.82% |
Technology
30.4
%
| 1,833 | 34.6 % | 950 | 30.4 % | -48.17% |
Service
0.1
%
| 19 | 0.4 % | 3 | 0.1 % | -84.36% |
Other
0.0
%
| 4 | 0.1 % | 0 | 0.0 % | -87.18% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
100.0
%
| 5,293 | 100.0 % | 3,125 | 100.0 % | -40.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Won-Il Yoo
CEO | Chief Executive Officer | 61 | 00-06-22 |
Myeong-Jae Rhee
DFI | Director of Finance/CFO | 54 | 12-04-30 |
Yang-Je Cho
CTO | Chief Tech/Sci/R&D Officer | 56 | 00-06-22 |
Jong-Doo Choi
AUD | Comptroller/Controller/Auditor | 55 | 12-02-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jong-Doo Choi
AUD | Comptroller/Controller/Auditor | 55 | 12-02-29 |
Won-Il Yoo
CEO | Chief Executive Officer | 61 | 00-06-22 |
Yang-Je Cho
CTO | Chief Tech/Sci/R&D Officer | 56 | 00-06-22 |
Dal-Hyun Kim
BRD | Director/Board Member | 62 | - |
Doo-Sik Kim
BRD | Director/Board Member | 73 | 15-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,029,784 | 19,457,203 ( 71.98 %) | 0 | 71.98 % |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
-33.18% | 55.77M | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- A185490 Stock
- Company EyeGene Inc.